Matthew Keller
Stock Analyst at HC Wainwright & Co.
(2.86)
# 1,830
Out of 5,044 analysts
8
Total ratings
75%
Success rate
17.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Keller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $31 | $6.30 | +392.06% | 2 | Sep 30, 2025 | |
| FGEN FibroGen | Reiterates: Buy | $43 | $10.83 | +297.23% | 2 | Sep 24, 2025 | |
| IFRX InflaRx | Assumes: Buy | $6 | $1.51 | +297.35% | 1 | Sep 2, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $18 | $7.72 | +133.16% | 1 | Aug 26, 2025 | |
| PHIO Phio Pharmaceuticals | Reiterates: Buy | $14 | $2.16 | +548.15% | 1 | Aug 15, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Buy | $6 | $5.09 | +17.88% | 1 | Aug 14, 2025 |
Acurx Pharmaceuticals
Sep 30, 2025
Reiterates: Buy
Price Target: $31
Current: $6.30
Upside: +392.06%
FibroGen
Sep 24, 2025
Reiterates: Buy
Price Target: $43
Current: $10.83
Upside: +297.23%
InflaRx
Sep 2, 2025
Assumes: Buy
Price Target: $6
Current: $1.51
Upside: +297.35%
Gyre Therapeutics
Aug 26, 2025
Initiates: Buy
Price Target: $18
Current: $7.72
Upside: +133.16%
Phio Pharmaceuticals
Aug 15, 2025
Reiterates: Buy
Price Target: $14
Current: $2.16
Upside: +548.15%
Galectin Therapeutics
Aug 14, 2025
Reiterates: Buy
Price Target: $6
Current: $5.09
Upside: +17.88%